Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034924.xml
CC BY 4.0 · Nuklearmedizin 2024; 63(02): 57-61
DOI: 10.1055/a-2194-9965
DOI: 10.1055/a-2194-9965
Original Article
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges
CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen
Abstract
C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.
Keywords
CXCR4 - chemokine receptor - theranostics - marginal zone lymphoma - T-cell lymphoma - [68Ga]Ga-PentixaForPublication History
Received: 09 August 2023
Accepted: 18 September 2023
Article published online:
08 January 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: Making precision medicine possible. CA Cancer J Clin 2023; 73 (03) 255-274 DOI: 10.3322/caac.21768. (PMID: 36622841)
- 2 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376 (02) 125-135 DOI: 10.1056/NEJMoa1607427. (PMID: 28076709)
- 3 Sartor O, de Bono J, Chi KN. et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2021; 385 (12) 1091-1103 DOI: 10.1056/NEJMoa2107322. (PMID: 34161051)
- 4 Buck AK, Serfling SE, Kraus S. et al. Theranostics in Hematooncology. J Nucl Med 2023; 64 (07) 1009-1016 DOI: 10.2967/jnumed.122.265199. (PMID: 37290799)
- 5 Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res 2014; 124: 31-82 DOI: 10.1016/B978-0-12-411638-2.00002-1. (PMID: 25287686)
- 6 Demmer O, Gourni E, Schumacher U. et al. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem 2011; 6 (10) 1789-1791 DOI: 10.1002/cmdc.201100320. (PMID: 21780290)
- 7 Shekhawat AS, Singh B, Malhotra P. et al. Imaging CXCR4 receptors expression for staging multiple myeloma by using (68)Ga-Pentixafor PET/CT: comparison with (18)F-FDG PET/CT. Br J Radiol 2022; 95: 20211272
- 8 Chen Z, Yang A, Zhang J. et al. CXCR4-Directed PET/CT with [(68)Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [(18)F]FDG PET/CT. Mol Imaging Biol 2022; 24 (03) 416-424
- 9 Duell J, Krummenast F, Schirbel A. et al. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. J Nucl Med 2021; 62 (10) 1415-1421 DOI: 10.2967/jnumed.120.257279. (PMID: 33579803)
- 10 Buck AK, Haug A, Dreher N. et al. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using (68)Ga-Pentixafor PET. J Nucl Med 2022; 63 (11) 1687-1692
- 11 Buck AK, Grigoleit GU, Kraus S. et al. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma. J Nucl Med 2023; 64 (01) 34-39
- 12 Buck AK, Serfling SE, Lindner T. et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging 2022; 49 (12) 4133-4144 DOI: 10.1007/s00259-022-05849-y. (PMID: 35674738)
- 13 Zucca E, Arcaini L, Buske C. et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31 (01) 17-29 DOI: 10.1016/j.annonc.2019.10.010. (PMID: 31912792)
- 14 Duell J, Schneid S, Kosmala A. et al. CXCR4-gerichtete PET/CT in 100 Patient:innen mit Marginalzonenlymphom -Diagnostische Performance, Vorhersagepotenzial und Eignung für CXCR4-Endoradiotherapie. Nuklearmedizin 2023; 62: 95
- 15 Zucca E, Dreyling M, Group EGW. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v175-176
- 16 Stollberg S, Kammerer D, Neubauer E. et al. Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. J Cancer Res Clin Oncol 2016; 142 (11) 2239-2247 DOI: 10.1007/s00432-016-2220-6. (PMID: 27544389)
- 17 Haug AR, Leisser A, Wadsak W. et al. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI. Theranostics 2019; 9 (12) 3653-3658 DOI: 10.7150/thno.31032. (PMID: 31281504)
- 18 Mayerhoefer ME, Raderer M, Lamm W. et al. CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication. Blood 2022; 139 (02) 240-244 DOI: 10.1182/blood.2021013239. (PMID: 34525196)
- 19 Herrmann K, Schottelius M, Lapa C. et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J Nucl Med 2016; 57 (02) 248-251
- 20 Sugiyama T, Kohara H, Noda M. et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25 (06) 977-988 DOI: 10.1016/j.immuni.2006.10.016. (PMID: 17174120)
- 21 Horwitz S, O’Connor OA, Pro B. et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019; 393: 229-240
- 22 Sabattini E, Pizzi M, Tabanelli V. et al. CD30 expression in peripheral T-cell lymphomas. Haematologica 2013; 98 (08) e81-82 DOI: 10.3324/haematol.2013.084913. (PMID: 23716537)
- 23 Saleh K, Michot JM, Ribrag V. Updates in the Treatment of Peripheral T-Cell Lymphomas. J Exp Pharmacol 2021; 13: 577-591 DOI: 10.2147/JEP.S262344. (PMID: 34188559)
- 24 Schottelius M, Herrmann K, Lapa C. In Vivo Targeting of CXCR4-New Horizons. Cancers (Basel) 2021; 13 (23) 5920 DOI: 10.3390/cancers13235920.. (PMID: 34885030)
- 25 Accessed June 09, 2023 at: https://pentixapharm.com/development-program.html
- 26 Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment (PentiMyelo). Accessed May 22, 2023 at: https://clinicaltrials.gov/ct2/show/NCT04561492?term=pentimyelo&draw=2&rank=1
- 27 In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET. Accessed May 22, 2023 at: https://clinicaltrials.gov/ct2/show/NCT05093335
- 28 Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR. Accessed May 22, 2023 at: https://pentixapharm.com/news.html